一種新型激光光束輸送系統(tǒng)利用光子能帶隙，通過(guò)柔性或者剛性?xún)?nèi)窺鏡輸送CO2激光。這套系統(tǒng)已經(jīng)獲得美國(guó)食品藥品管理局的許可，用于多種適應(yīng)癥。

CO2激光波長(zhǎng)是微米，具有獨(dú)特的組織相互作用特點(diǎn)，包括高度局限的熱效應(yīng)，極低的和可控制的穿透深度，還能夠凝固小~中等的血管。迄今為止，還沒(méi)有能夠完全輸送CO2激光光束的柔性輸送機(jī)制。OmniGuide Beam Path CO2 Mark I激光光束輸送系統(tǒng)利用光子能帶隙技術(shù)使用中空纖維戰(zhàn)勝了這種挑戰(zhàn)，該技術(shù)是由麻省理工學(xué)院的Yoel Fink教授研制開(kāi)發(fā)的。

FDA已經(jīng)批準(zhǔn)這套系統(tǒng)用于切割、切除、消融、汽化以及凝固機(jī)體軟組織，包括口腔內(nèi)的組織，適用于普通外科與整形外科、口腔/上頜面外科/皮膚科，以及與婦科、耳鼻喉科、消化科、神經(jīng)外科和肺臟手術(shù)麻醉相關(guān)的內(nèi)窺鏡、開(kāi)腹手術(shù)。

激光束輸送系統(tǒng)是由OmniGuide公司研制開(kāi)發(fā)的，這家公司是由Fink教授和他的同事創(chuàng)辦的。該公司從麻省理工學(xué)院獲得了全方位反射鏡。

OmniGuide公司總裁兼首席執(zhí)行官Steve Sheng博士說(shuō)：“FDA批準(zhǔn)我們公司的柔性纖維CO2輸送系統(tǒng)是我們核心醫(yī)學(xué)事業(yè)的巨大成功。FDA的批準(zhǔn)將允許OmniGuide能夠完全投入人類(lèi)手術(shù)市場(chǎng)，并將新型微創(chuàng)治療手術(shù)推進(jìn)到更多的專(zhuān)業(yè)之中。”
 
New Laser for Minimally Invasive Surgery
 
A new laser beam delivery system based on photonic bandgap technology delivers CO2 laser light through flexible or rigid endoscopes. The system has been cleared by the U.S. Food and Drug Administration (FDA) for multiple indications.

The CO2 laser wavelength, at 10.6 microns, offers unique tissue interaction characteristics that include highly localized thermal effects, ultra-low and controllable depth of penetration, as well as the ability to coagulate small-to-medium blood vessels. Until now, there has been no adequate flexible delivery mechanism for CO2 laser beams. The OmniGuide Beam Path CO2 Mark I laser beam delivery system has overcome this challenge by utilizing a hollow-core fiber based on photonic bandgap technology developed at the Massachusetts Institute of Technology (MIT, Boston, USA) by Prof. Yoel Fink.

The FDA has cleared the system for the incision, excision, ablation, vaporization, and coagulation of body soft tissues, including intraoral tissues, in the medical specialties of general and plastic surgery, oral/maxillofacial surgery, dermatology, endoscope and open surgical procedures related to gynecology, otorhinolaryngology, gastroenterology, neurosurgery, and pulmonary surgery for surgical and aesthetic applications.

The laser beam delivery system was developed by OmniGuide, Inc. (Cambridge, MA, USA), a company founded by Prof. Fink and colleagues. The company has an exclusive license from MIT on omnidirectional reflectors.

“The FDA clearance of our flexible fiber delivery system for CO2 lasers is a huge step forward for our core medical business,” observed Dr. Steve Sheng, president and CEO of OmniGuide. “The clearance will allow OmniGuide to fully engage the human surgical market and drive new minimally invasive treatment modalities in multiple specialties.”